Herein, we report two patients with resistance to first- and third-generation TKIs who benefited from second-generation TKI.<h4>Case summary</h4>Case one: A 43-year-old man was diagnosed with stage 3A NSCLC with EGFR exon 19 deletion. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.